In Final Guidance On Residual Solvents, FDA Allows Control, Not Just Testing, Verification
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency accepts industry comments on testing issue, but document may still contain hurdles for approval of some generic drugs.
You may also be interested in...
FDA Offers More Flexibility on Residual Solvents in Generic Drug Applications
FDA's Office of Generic Drugs has taken a more flexible approach in implementing the U.S. Pharmacopeia's General Chapter <467> on residual solvents
Generic Firms Object To Policy Behind Residual Solvents Deficiency Letters
FDA's Office of Generic Drugs has interpreted a new pharmacopoeial standard for residual solvents in an unexpectedly rigorous manner, rejecting dozens of applications and raising the ire of generic drug manufacturers
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.